Elia M. Pestana Knight

Elia M. Pestana Knight

Auto-generated profile, based on publicly available information

Elia M. Pestana Knight

Epilepsy Center, Neurological Institute, Cleveland Clinic, OH

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 April 2022 in The Lancet Neurology
Verified
Journal Article
Closed access
EKElia M Pestana Knight
Elia M Pestana Knight
SASam Amin
Sam Amin
NBNadia Bahi-Buisson
Nadia Bahi-Buisson
TBTim A Benke
Tim A Benke
JCJ Helen Cross
J Helen Cross
MZMarta Zolnowska
Marta Zolnowska

28 May 2022 in CNS Drugs
Verified
Journal Article
Open access
PDF file
WHWilliam Hong
William Hong
IHIsabel Haviland
Isabel Haviland
EPElia Pestana-Knight
Elia Pestana-Knight
JWJudith L. Weisenberg
Judith L. Weisenberg
SDScott Demarest
Scott Demarest
HOHeather E. Olson
Heather E. Olson
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is a developmental and epileptic encephalopathy with infantile-onset epilepsy. Most individuals with CDD develop refractory epilepsy with multiple seizure types. Management of seizures in CDD remains challenging for clinicians given the highly refractory nature of seizures and the limited number of disease-specific studies that offer a high level of evidence. Epileptic spasms are the most common seizure type in CDD and are more often refractory to standard first-line treatment than are spasms of other etiologies. In other seizure types, the effectiveness of antiseizure medications is limited and wanes over time. Ketogenic diet and palliative surgical treatments have both had mixed results in observational studies. When treating refractory seizures in CDD, we recommend carefully balancing seizure control and treatment-related side effects to optimize each individual’s overall quality of life. Clinical trials of medications targeting epilepsy in CDD have been conducted, and additional investigational small molecules, gene therapy, and other disease-modifying therapies are in development for CDD.

20 January 2021 in The Journal of Pediatrics
Verified
Journal Article
Closed access
FBFiona M. Baumer
Fiona M. Baumer
NMNancy A. McNamara
Nancy A. McNamara
AFAnthony L. Fine
Anthony L. Fine
EPElia Pestana-Knight
Elia Pestana-Knight
RSRenée A. Shellhaas
Renée A. Shellhaas
KCKevin E. Chapman
Kevin E. Chapman

1 August 2021 in Pediatric Neurology
Verified
Journal Article
Closed access
IZIfrah Zawar
Ifrah Zawar
EKElia Pestana Knight
Elia Pestana Knight

9 October 2014 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Open access
PDF file
LCLi Chen
Li Chen
EKElia M. Pestana Knight
Elia M. Pestana Knight
ITIngrid Tuxhorn
Ingrid Tuxhorn
ASAsim Shahid
Asim Shahid
HLHans O. Lüders
Hans O. Lüders
Aim: The aim of this study was to analyze in detail the clinical phenomenology of paroxysmal non‐epileptic events (PNEE) in infants and toddlers.Methods: We studied all children aged ≤2 years who were diagnosed with PNEE based on video‐electroencephalographic (VEEG) recordings. We analyzed the following four clinical domains of each clinical event: (i) motor manifestations (body/limb jerking, complex motor, and asymmetric limb posturing); (ii) oral/vocal (crying, vocalization, sighing); (iii) behavioral change (arrest of activity, staring); (iv) and autonomic (facial flushing, breath holding).Results: Thirty‐one of 81 (38.3%) infants and toddlers had 38 PNEE recorded during the study period (12 girls and 19 boys, mean age 10.5 months). The predominant clinical features were as follows: motor in 26/38 events, oral/verbal in 14/38 events, behavioral in 11/38 events, and autonomic in 8/38 events. Epileptic seizures and PNEE coexisted in four children (12.9%). Seventeen children (54.8%) had one or more risk factors suggestive of epilepsy. Twelve children (38.7%) had a normal neurologic examination, 10 (32.3%) had developmental delay, and eight (25.8%) had a family history of epilepsy or seizures.Conclusion: VEEG recorded PNEE in nearly 40% of 81 infants and toddlers referred for unclear paroxysmal events in our cohort. Non‐epileptic staring spells and benign sleep myoclonus were the most common events recorded, followed by shuddering attacks and infantile masturbation. In addition, greater than one‐half of the infants and toddlers had risk factors, raising a concern for epilepsy in the family and prompting the VEEG evaluation, suggesting that paroxysmal non‐epileptic seizures may frequently coexist in young children with epilepsy.

29 November 2023 in Epilepsia
Verified
Journal Article
Open access
HOHeather E. Olson
Heather E. Olson
SASam Amin
Sam Amin
NBNadia Bahi‐Buisson
Nadia Bahi‐Buisson
ODOrrin Devinsky
Orrin Devinsky
EMEric D. Marsh
Eric D. Marsh
SDScott Demarest
Scott Demarest
Objective: In the placebo‐controlled, double‐blind phase of the Marigold study (NCT03572933), ganaxolone significantly reduced major motor seizure frequency (MMSF) in patients with cyclin‐dependent kinase‐like 5 deficiency disorder (CDD). We report 2‐year safety and clinical outcomes data from the open‐label extension (OLE) phase of Marigold.Methods: Patients with CDD who completed the double‐blind phase were eligible to continue in the OLE. Efficacy assessments included MMSF reduction from prerandomization baseline, responder rates, and Clinical Global Impression–Improvement scores, including assessment of seizure intensity and duration (CGI‐CSID). Safety assessments included treatment‐emergent adverse events (TEAEs) and TEAEs leading to discontinuation.Results: Of 101 patients who enrolled in Marigold, 88 (87.1%) entered the OLE (median age = 5 years, 79.5% female). Median 28‐day MMSF at baseline was 50.6. At 2 years in the OLE (months 22–24), MMSF was reduced by a median of 48.2% (n = 50); when missing data were imputed, median reduction in MMSF was 43.8% using a mixed effects model and 27.4% using a last observation carried forward model. During months 22–24, 23 of 50 (46.0%) patients experienced reductions in MMSF of ≥50%; 12 of 50 (24.0%) patients experienced MMSF reductions of ≥75%. During months 22–24, 40 of 49 (81.6%) patients were rated by caregivers as having improvement in seizure‐related outcomes based on CGI‐CSID scores. Thirty‐seven patients discontinued ganaxolone due to lack of efficacy (n = 13), withdrawal by caregiver (n = 12), adverse event (n = 10), physician decision (n = 1), or death (n = 1; unrelated to study drug). The most common treatment‐related TEAEs were somnolence (17.0%), seizure (11.4%), and decreased appetite (5.7%). Patients reported serious TEAEs (n = 28, 31.8%); those reported in ≥3% of patients were seizure (n = 6), pneumonia (n = 5), acute respiratory failure (n = 3), aspiration pneumonia (n = 3), and dehydration (n = 3).Significance: Sustained reductions in MMSF at 2 years in the OLE support the efficacy of ganaxolone in seizures associated with CDD. Safety findings in the OLE were consistent with the double‐blind phase.